

International MI Profile™ Associations List

The profile menu below details the biomarkers assessed, technology platforms utilized and associated therapies or clinical trials reported. **Biomarkers and therapy associations may vary by the tumour type submitted.** The current and definitive MI Profile™ menu can be found online at www.CarisMolecularIntelligence.com/profilemenu.

Therapy association(s) and platform may vary based on the tumour type submitted for profiling. Individual assay results are always included with the final report.

Agent	Biomarker	Platform	Agent	Biomarker	Platform
afatinib (assoc. in NSCLC only)	EGFR	NGS	everolimus, temsirolimus	ER (assoc. in Breast only)	IHC
	ERBB2 (Her2)	NGS		PIK3CA (excluding CRC)	NGS
afatinib + cetuximab (combination assoc. in NSCLC only)	EGFR T790M	NGS	gemcitabine	RRM1	IHC
alectinib, ceritinib	ALK	IHC	hormone therapies ² (excluding CRC, Melanoma, NSCLC)	AR (excluding Ovarian)	IHC
aspirin (assoc. in CRC only)	PIK3CA	NGS		ER (excluding Prostate)	IHC
cabozantinib (assoc. in NSCLC only)	cMET	NGS		PR (excluding Prostate)	IHC
capecitabine, fluorouracil, pemetrexed	TS	IHC	imatinib	cKIT	NGS
carboplatin, cisplatin, oxaliplatin	BRCA1	NGS		PDGFRA	NGS
	BRCA2	NGS	irinotecan	TOPO1 (excluding Breast, CRC, Melanoma, NSCLC)	IHC
	ERCC1	IHC	topotecan		
cetuximab, panitumumab ² (assoc. in CRC only)	BRAF	NGS	lapatinib, pertuzumab, T-DM1	Her2/Neu	IHC; CISH
	KRAS	NGS	lomustine, procarbazine, vincristine	1p19q	FISH
	NRAS	NGS	mitomycin-c	BRCA1	NGS
	PIK3CA	NGS		BRCA2	
	PTEN	IHC	nivolumab, pembrolizumab (assoc. in Bladder, Kidney, Melanoma, NSCLC only)	PD-L1	IHC
cetuximab	EGFR	CISH	olaparib (assoc. in Ovarian only)	BRCA1	NGS
crizotinib (assoc. in NSCLC only)	ALK	IHC		BRCA2	
	cMET	CISH, NGS	osimertinib (assoc. in NSCLC only)	EGFR T790M	NGS
	ROS1	FISH	palbociclib (assoc. in Breast only)	ER	IHC
dabrafenib, vemurafenib ¹	BRAF	NGS		Her2/Neu	IHC; CISH
dacarbazine, temozolomide	MGMT	IHC	sunitinib (assoc. in GIST only)	cKIT	NGS
	MGMT-Methylation	Pyrosequencing	trametinib ¹ (assoc. in Melanoma only)	BRAF	NGS
	IDH1 (assoc. in High Grade Glioma only)	NGS		ERBB2 (Her2) (assoc. in NSCLC only)	NGS
docetaxel, paclitaxel, nab-paclitaxel	TLE3 (excluding Breast)	IHC	trastuzumab	Her2/Neu	IHC; CISH
	TUBB3 (excluding Breast)	IHC		PTEN (assoc. in Breast only)	IHC
doxorubicin, liposomal-doxorubicin, epirubicin	TOP2A	IHC (excluding Breast)		PIK3CA (assoc. in Breast only)	NGS
		CISH		RET	NGS
erlotinib, gefitinib (assoc. in NSCLC only)	EGFR	NGS			
	KRAS	NGS			
	PIK3CA	NGS			
	cMET	CISH			
	PTEN	IHC			

IHC: Immunohistochemistry **CISH:** Chromogenic *in situ* Hybridization **FISH:** Fluorescence *in situ* Hybridization **NGS:** Next-Generation Sequencing

Note: Biomarkers listed above may also be assessed for clinical trial opportunities and may include clinical trials associations.

¹ In CRC, cetuximab/panitumumab, vemurafenib/dabrafenib, and trametinib may be reported in combination.

² Hormone therapies may include: tamoxifen, toremifene, fulvestrant, letrozole, anastrozole, exemestane, megestrol acetate, leuprolide, goserelin, bicalutamide, flutamide, abiraterone, enzalutamide, triptorelin, abarelix, degarelix.

International MI Profile™ Testing List

The profile testing list below details the biomarkers analyzed by technology platform. Before ordering testing services, please refer to the profile menu online (www.CarisMolecularIntelligence.com/profilemenu) to view the most up-to-date listing of biomarkers that will be performed. Tests may vary if insufficient tumour samples are submitted. Please refer to the technical specifications below for more information.

MI Profile™					
Immunohistochemistry (IHC)	Chromogenic <i>in situ</i> Hybridization (CISH)	Fluorescence <i>in situ</i> Hybridization (FISH) ¹	Next-Generation Sequencing	Fragment Analysis	Pyro Sequencing
ALK (<i>NSCLC only</i>), AR, ER, ERCC1, HER2, MGMT ² , MLH1 ² , MSH2 ² , MSH6 ² , PD-L1, PMS2 ² , PR, PTEN, RRM1, TLE3 (<i>breast only</i>), TOP2A, TOPO1, TS, TUBB3	cMET (<i>NSCLC only</i>), EGFR (<i>NSCLC only</i>), HER2, TOP2A (<i>breast only</i>)	1p19q (<i>glioma only</i>), ROS1 (<i>NSCLC only</i>)	See MI Profile™ Next-Generation Sequencing Genes (<i>below</i>)	EGFRvIII (<i>glioma only</i>), MSI ²	MGMT Methylation Analysis (<i>glioma only</i>)

¹ Assay(s) may be performed by an external reference laboratory. ² Assay performed in CRC and Endometrial only.

MI Profile Expanded NGS Gene List

Point Mutations and Indels									
ABI1	BRD4	CRLF2	FOXO4	HOXC11	KLF4	MUC1	PAK3	RHOH	TAL2
ABL1	BTG1	DDB2	FSTL3	HOXC13	KLK2	MUTYH	PATZ1	RNF213	TBL1XR1
ACKR3	BTIK	DDIT3	GATA1	HOXD11	LASP1	MYCL (MYCL1)	PAX8	RPL10	TCEA1
AKT1	C15orf65	DNM2	GATA2	HOXD13	LMO1	NBN	PDEADIP	SEPT5	TCL1A
AMER1 (FAM123B)	CBLC	DNMT3A	GNA11	HRAS	LMO2	NDRG1	PHF6	SEPT6	TERT
AR	CD79B	EIF4A2	GPC3	IKBKE	MAFB	NKX2-1	PHOX2B	SFPQ	TFE3
ARAF	CDH1	ELF4	HEY1	INHBA	MAX	NONO	PIK3CG	SLC45A3	TFPT
ATP2B3	CDK12	ELN	HIST1H3B	IRS2	MECOM	NOTCH1	PLAG1	SMARCA4	THRAP3
ATRX	CDKN2B	ERCC1	HIST1H4I	JUN	MED12	NRAS	PMS1	SOC51	TLX3
BCL11B	CDKN2C	ETV4	HLF	KAT6A (MYST3)	MKL1	NUMA1	POU5F1	SOX2	TMPRSS2
BCL2	CEBPA	FAM46C	HMG2P46	KAT6B	MLLT11	NUTM2B	PPP2R1A	SPOP	UBR5
BCL2L2	CHCHD7	FANCF	HNF1A	KCNJ5	MN1	OLIG2	PRF1	SRC	VHL
BCOR	CNOT3	FEV	HOXA11	KDM5C	MPL	OMD	PRKDC	SSX1	WAS
BCORL1	COL1A1	FOXL2	HOXA13	KDM6A	MSN	P2RY8	RAD21	STAG2	ZBTB16
BRD3	COX6C	FOXO3	HOXA9	KDSR	MTC1	PAFAH1B2	RECQL4	TAL1	ZRSR2

Point Mutations, Indels and Copy Number Variations									
ABL2	BRCA2	COPB1	ESR1	FUS	KIT	MYB	PER1	RUNX1	TFG
ACSL3	BRIP1	CREB1	ETV1	GA57	KLHL6	MYC	PICALM	RUNX1T1	TFR
ACSL6	BUB1B	CREB3L1	ETV5	GATA3	KMT2A (MLL)	MYCN	PIK3CA	SBOS	TGFB2
AFF1	C11orf30 (EMSY)	CREB3L2	ETV6	GID4 (C17orf39)	KMT2C (MLL3)	MYD88	PIK3R1	SDC4	TLX1
AFF3	C2orf44	CREBBP	EWSR1	GMP5	KMT2D (MLL2)	MYH11	PIK3R2	SDHAF2	TNFAIP3
AFF4	CACNA1D	CRKL	EXT1	GNA13	KRAS	MYH9	PIM1	SDHB	TNFRSF14
AKAP9	CALR	CRTC1	EXT2	GNAQ	KTN1	NACA	PML	SDHC	TNFRSF17
AKT2	CAMTA1	CRTC3	EZH2	GNAS	LCK	NCKIPSD	PMS2	SDHD	TOP1
AKT3	CANT1	CSF1R	EZR	GOLGA5	LCP1	NCOA1	POLE	SEPT9	TP53
ALDH2	CARD11	CSF3R	FANCA	GOPC	LGR5	NCOA2	POT1	SET	TPM3
ALK	CARS	CTCF	FANCC	GPHN	LHFP	NCOA4	POU2AF1	SETBP1	TPM4
APC	CASC5	CTLA4	FANCD2	GPR124	LIFR	NF1	PPARG	SETD2	TPR
ARFRP1	CASP8	CTNNA1	FANCE	GRIN2A	LPP	NF2	PRCC	SF3B1	TRAF7
ARHGAP26	CBFA2T3	CTNBN1	FANCG	GSK3B	LRI3	NFE2L2	PRDM1	SH2B3	TRIM26
ARHGEF12	CBFB	CYLD	FANCL	H3F3A	LRP1B	NFIB	PRDM16	SH3GL1	TRIM27
ARID1A	CBL	CYP2D6	FAS	H3F3B	LYL1	NFKB2	PRKAR1A	SLC34A2	TRIM33
ARID2	CBLL	DAXX	FBXO11	HERPUD1	MAF	NFKBIA	PRRX1	SMAD2	TRIP11
ARNT	CCDC6	DDR2	FBXW7	HGF	MALT1	NIN	PSIP1	SMAD4	TRRAP
ASPSR1	CCNB1IP1	DDX10	FCRL4	HIP1	MAML2	NOTCH2	PTCH1	SMARCB1	TSC1
ASXL1	CCND1	DDX5	FGF10	HMGAI	MAP2K1	NPM1	PTEN	SMARCE1	TSC2
ATF1	CCND2	DDX6	FGF14	HMGAI2	MAP2K2	NR4A3	PTPN11	SMO	TSHR
ATIC	CCND3	DEK	FGF19	HNRNP2B1	MAP2K4	NSD1	PTPRC	SNX29	TTL
ATM	CCNE1	DICER1	FGF23	HOOK3	MAP3K1	NTSC2	RABEP1	SOX10	U2AF1
ATP1A1	CD274 (PDL1)	DOT1L	FGF3	HSP90AA1	MCL1	NTRK1	RAC1	SPECC1	USP6
ATR	CD74	EBF1	FGF4	HSP90AB1	MDM2	NTRK2	RAD50	SPEN	VEGFA
AURKA	CD79A	ECT2L	FGF6	IDH1	MDM4	NTRK3	RAD51	SRGAP3	VEGFB
AURKB	CDK3	EGFR	FGFR1	IDH2	MDS2	NUP214	RAD51B	SRSF2	VTG1A
AXIN1	CDH11	ELK4	FGFR1OP	IGF1R	MEF2B	NUP93	RAF1	SRSF3	WHSC1
AXL	CDK4	ELL	FGFR2	IKZF1	MEN1	NUP98	RALGDS	SS18	WHSC1L1
BAP1	CDK6	EML4	FGFR3	IL2	MET (cMET)	NUTM1	RANBP17	SS18L1	WIF1
BARD1	CDK8	EP300	FGFR4	IL21R	MITF	PALB2	RAP1GDS1	STAT3	WISP3
BCL10	CDKN1B	EPHA3	FH	IL6ST	MLF1	PAX3	RARA	STAT4	WRN
BCL11A	CDKN2A	EPHA5	FHIT	IL7R	MLH1	PAX5	RB1	STAT5B	WT1
BCL2L11	CDX2	EPHB1	FIP1L1	IRF4	MLLT1	PAX7	RBM15	STIL	WWTR1
BCL3	CHEK1	EP515	FLCN	ITK	MLLT10	PBRM1	REL	STK11	XPA
BCL6	CHEK2	ERBB2 (HER2)	FLI1	JAK1	MLLT3	PBX1	RET	SUFU	XPC
BCL7A	CHIC2	ERBB3 (HER3)	FLT1	JAK2	MLLT4	PCMK1	RICTOR	SUZ12	XPO1
BCL9	CHN1	ERBB4 (HER4)	FLT3	JAK3	MLLT6	PCSK7	RII2	SYK	YWHA
BCR	CIC	ERC1	FLT4	JAZF1	MXN1	PDCD1 (PD1)	RNF43	TAF15	ZMYM2
BIRC3	CLTA	ERCC2	FNBP1	KDM5A	MRE11A	PDCD1LG2 (PDL2)	ROS1	TCF12	ZNF217
BLM	CLP1	ERCC3	FOXA1	KDR (VEGFR2)	MSH2	PDGFB	RPL22	TCF3	ZNF331
BMPR1A	CLTC	ERCC4	FOXO1	KEAP1	MSH6	PDGFRA	RPL5	TCF7L2	ZNF384
BRAF	CLTCL1	ERCC5	FOXP1	KIAA1549	MSI2	PDGFRB	RPN1	TET1	ZNF521
BRCA1	CNBP	ERG	FUBP1	KIF5B	MTOR	PKD1	RPTOR	TET2	ZNF703
	CNTRL							TFEB	

In certain instances, some biomarkers included in MI Profile or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.

To order or learn more, visit www.CarisMolecularIntelligence.com.

US: 888.979.8669 | MIClientServices@carisls.com

Intl: 00 41 21 533 53 00 | EUCustomerServices@carisls.com



Caris Molecular Intelligence is a trademark of Caris Life Sciences.
© 2016 Caris Life Sciences. All rights reserved. TN9152 v5 February 25, 2016